Download Files:
AMD 3465 (hexahydrobromide)
$61 – $528
Products Details
Product Description
– AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
Web ID
– HY-15971
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C24H44Br6N6
Citations
– Biomed Pharmacother. 2021 Mar 24;138:111476.|J Labelled Comp Radiopharm. 2018 May 15;61(5):438-446. |Patent. US20180263995A1.|Br J Haematol. 2022 Dec 19.
References
– [1]Hatse S, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol. 2005 Sep 1;70(5):752-61.|[2]Yang L, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007 Jan 15;67(2):651-8.
CAS Number
– 185991-07-5
Molecular Weight
– 896.07
Compound Purity
– 98.0
SMILES
– [H]Br.[H]Br.[H]Br.[H]Br.[H]Br.[H]Br.C1(CNCC2=CC=C(CN3CCNCCCNCCNCCC3)C=C2)=NC=CC=C1
Clinical Information
– No Development Reported
Research Area
– Infection; Endocrinology
Solubility
– DMSO : 50 mg/mL (ultrasonic)|H2O : ≥ 38 mg/mL
Target
– CXCR;HIV
Isoform
– CXCR4;HIV-1;HIV-2
Pathway
– Anti-infection;GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
